SCI Pharmtech, Inc. (TPE:4119)

Market Cap	10.36B
Revenue (ttm)	1.41B
Net Income (ttm)	484.24M
Shares Out	119.51M
EPS (ttm)	4.08
PE Ratio	21.25
Forward PE	20.07
Dividend	1.25 (1.44%)
Ex-Dividend Date	n/a

Volume	77,023
Average Volume	115,958
Open	86.80
Previous Close	86.60
Day's Range	86.30 - 86.90
52-Week Range	82.50 - 98.50
Beta	-0.28
RSI	48.43
Earnings Date	Mar 18, 2025

About SCI Pharmtech

SCI Pharmtech, Inc., together with its subsidiary, engages in the research and development, manufacture, and sale of active pharmaceutical ingredients, intermediates, and specialty chemicals in Italy, the United States, Japan, Germany, Taiwan, Switzerland, China, and internationally. The company offers active pharmaceutical ingredients, including adenine, articaine HCl, atomoxetine HCl, bisoprolol hemifumarate, brinzolamide, buprenorphine and buprenorphine HCl, cannabidol, divalproex sodium, duloxetine HCl, hydroxychloroquine sulfate, loxoprofe...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1987
• Employees: 239
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 4119

Financial Performance

In 2023, SCI Pharmtech's revenue was 1.20 billion, an increase of 33.83% compared to the previous year's 899.74 million. Earnings were 294.72 million, a decrease of -4.55%.